ANI Pharmaceuticals, Inc.(ANIP)Earnings, Financials & Key Ratios

ANIP•NASDAQ

$84.06

$1.78B mkt cap·25.3× P/E·Price updated May 6, 2026

SectorHealthcare IndustrySpecialty & Generic Pharma Sub-IndustryComplex generics and injectables

AboutANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.Show more

Revenue$883M+43.8%
EBITDA$203M+196.4%
Net Income$78M+522.9%
EPS (Diluted)3.32+419.2%
EBITDA Margin22.92%+106.2%
Operating Margin12.58%+13124.1%
Net Margin8.87%+394.1%
ROE16.16%+486.7%
ROIC11.2%+18167.9%
Debt/Equity0.60-58.7%

Technical→

ANIP Key Insights

ANI Pharmaceuticals, Inc. (ANIP) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓FCF machine: 21.0% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 33.5%

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

ANIP Price & Volume

ANI Pharmaceuticals, Inc. (ANIP) stock price & volume — 10-year historical chart

Loading chart...

ANIP Growth Metrics

ANI Pharmaceuticals, Inc. (ANIP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years27.75%

5 Years33.48%

3 Years40.81%

TTM43.78%

Profit CAGR

10 Years17.68%

5 Years-

3 Years-

TTM522.94%

EPS CAGR

10 Years9.66%

5 Years-

3 Years-

TTM393.81%

Return on Capital

10 Years3.14%

5 Years0.77%

3 Years5.52%

Last Year9.86%

ANIP Recent Earnings

ANI Pharmaceuticals, Inc. (ANIP) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 12/12 qtrs (100%)●Beat Revenue 10/12 qtrs (83%)

Q1 2026Latest

Feb 27, 2026

EPS

$2.33

Est $1.99

+17.1%

Revenue

$247M

Est $231M

+6.9%

Q4 2025

Nov 7, 2025

EPS

$2.04

Est $1.74

+17.2%

Revenue

$228M

Est $232M

-1.9%

Q3 2025

Aug 8, 2025

EPS

$1.80

Est $1.38

+30.4%

Revenue

$211M

Est $209M

+1.2%

Q2 2025

May 9, 2025

EPS

$1.70

Est $1.37

+24.1%

Revenue

$197M

Est $189M

+4.4%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 27, 2026	$2.33vs $1.99+17.1%	$247Mvs $231M+6.9%
Q4 2025	Nov 7, 2025	$2.04vs $1.74+17.2%	$228Mvs $232M-1.9%
Q3 2025	Aug 8, 2025	$1.80vs $1.38+30.4%	$211Mvs $209M+1.2%
Q2 2025	May 9, 2025	$1.70vs $1.37+24.1%	$197Mvs $189M+4.4%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
AMRXAmneal Pharmaceuticals, Inc.Direct Competitor	4.28B	13.62	61.91	8.05%	2.39%	7.47%	0.13
LNTHLantheus Holdings, Inc.Direct Competitor	5.61B	86.15	25.26	0.5%	15.15%	20.58%	0.00
PRGOPerrigo Company plcDirect Competitor	1.69B	12.26	-1.19	-2.75%	-43.5%	-50.65%	1.35
PAHCPhibro Animal Health CorporationDirect Competitor	2.38B	58.64	49.28	27.37%	6.29%	30.81%	2.67
SUPNSupernus Pharmaceuticals, Inc.Direct Competitor	2.96B	51.45	-75.66	8.63%	-3.74%	-2.73%	0.04
HIHillenbrand, Inc.Product Competitor	2.26B	31.98	52.43	-15.99%	1.37%	2.43%	1.12
SLDBSolid Biosciences Inc.Product Competitor	560.76M	7.20	-3.62			-73.63%	0.12
VTRSViatris Inc.Product Competitor	18.37B	15.95	-5.32	-2.98%	-24.58%	-23.89%	0.98

Compare ANIP vs Peers

ANI Pharmaceuticals, Inc. (ANIP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs AMRX

Most directly comparable listed peer for ANIP.

Scale Benchmark

vs MCK

Larger-name benchmark to compare ANIP against a more recognizable public peer.

Peer Set

Compare Top 5

vs AMRX, LNTH, PRGO, PAHC

ANIP Income Statement

ANI Pharmaceuticals, Inc. (ANIP) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	176.84M	201.58M	206.55M	208.47M	216.14M	316.38M	486.82M	614.38M	883.37M
Revenue Growth %	37.49%	13.99%	2.47%	0.93%	3.67%	46.38%	53.87%	26.2%	43.78%
Cost of Goods Sold	79.03M	73.02M	63.15M	87.16M	100.61M	138.78M	181.51M	250.21M	0
COGS % of Revenue	44.69%	36.23%	30.58%	41.81%	46.55%	43.87%	37.29%	40.73%	-
Gross Profit	97.81M▲ 0%	128.55M▲ 31.4%	143.39M▲ 11.5%	121.32M▼ 15.4%	115.53M▼ 4.8%	177.6M▲ 53.7%	305.3M▲ 71.9%	364.17M▲ 19.3%	0▼ 100.0%
Gross Margin %	55.31%	63.77%	69.42%	58.19%	53.45%	56.13%	62.71%	59.27%	-
Gross Profit Growth %	22.5%	31.43%	11.54%	-15.39%	-4.77%	53.73%	71.9%	19.28%	-100%
Operating Expenses	68.58M	93.19M	127.04M	137.33M	155.32M	212.88M	258.33M	363.58M	772.27M
OpEx % of Revenue	38.78%	46.23%	61.51%	65.88%	71.86%	67.29%	53.07%	59.18%	87.42%
Selling, General & Admin	31.58M	44.06M	55.84M	64.99M	84.29M	124.04M	161.7M	249.64M	317.75M
SG&A % of Revenue	17.86%	21.86%	27.04%	31.17%	39%	39.21%	33.22%	40.63%	35.97%
Research & Development	9.07M	15.39M	19.81M	16M	11.37M	22.32M	34.29M	44.58M	51.66M
R&D % of Revenue	5.13%	7.63%	9.59%	7.68%	5.26%	7.05%	7.04%	7.26%	5.85%
Other Operating Expenses	55K	-550K	51.39M	56.35M	59.66M	66.52M	62.35M	69.36M	402.86M
Operating Income	28.33M▲ 0%	35.36M▲ 24.8%	16.35M▼ 53.8%	-16.02M▼ 198.0%	-39.79M▼ 148.5%	-35.28M▲ 11.3%	46.97M▲ 233.1%	584K▼ 98.8%	111.09M▲ 18922.8%
Operating Margin %	16.02%	17.54%	7.92%	-7.68%	-18.41%	-11.15%	9.65%	0.1%	12.58%
Operating Income Growth %	41.09%	24.82%	-53.76%	-197.95%	-148.46%	11.33%	233.13%	-98.76%	18922.77%
EBITDA	56.26M	69.1M	60.96M	28.62M	7.46M	24.37M	106.76M	68.31M	202.51M
EBITDA Margin %	31.81%	34.28%	29.52%	13.73%	3.45%	7.7%	21.93%	11.12%	22.92%
EBITDA Growth %	32.61%	22.83%	-11.78%	-53.05%	-73.94%	226.72%	338.09%	-36.01%	196.44%
D&A (Non-Cash Add-back)	27.93M	33.74M	44.61M	44.64M	47.25M	59.65M	59.79M	67.73M	91.42M
EBIT	29.23M	34.81M	16.12M	-16.51M	-44.14M	-34.61M	46.81M	-4.61M	0
Net Interest Income	-12.04M	-14.76M	-12.97M	-9.45M	-11.92M	-28.05M	-26.94M	-17.6M	0
Interest Income	0	0	0	0	0	0	0	0	0
Interest Expense	12.04M	14.76M	12.97M	9.45M	11.92M	28.05M	26.94M	17.6M	-20.06M
Other Income/Expense	-11.98M	-15.31M	-13.19M	-9.95M	-16.27M	-27.38M	-27.1M	-22.8M	-15.3M
Pretax Income	16.35M▲ 0%	20.05M▲ 22.6%	3.16M▼ 84.3%	-25.96M▼ 922.4%	-56.06M▼ 115.9%	-62.66M▼ 11.8%	19.87M▲ 131.7%	-22.21M▼ 211.8%	95.79M▲ 531.3%
Pretax Margin %	9.25%	9.95%	1.53%	-12.45%	-25.94%	-19.81%	4.08%	-3.62%	10.84%
Income Tax	17.43M	4.56M	-2.94M	-3.41M	-13.46M	-14.77M	1.09M	-3.69M	17.45M
Effective Tax Rate %	106.58%	22.73%	-93.03%	13.15%	24%	23.57%	5.5%	16.61%	18.22%
Net Income	-1.08M▲ 0%	15.49M▲ 1540.0%	6.09M▼ 60.7%	-22.55M▼ 470.0%	-42.6M▼ 88.9%	-47.9M▼ 12.4%	18.78M▲ 139.2%	-18.52M▼ 198.6%	78.34M▲ 522.9%
Net Margin %	-0.61%	7.69%	2.95%	-10.82%	-19.71%	-15.14%	3.86%	-3.01%	8.87%
Net Income Growth %	-127.35%	1539.96%	-60.67%	-470%	-88.94%	-12.42%	139.21%	-198.63%	522.94%
Net Income (Continuing)	-1.08M	15.49M	6.09M	-22.55M	-42.6M	-47.9M	18.78M	-18.52M	78.34M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-0.09▲ 0%	1.32▲ 1516.3%	0.50▼ 62.1%	-1.88▼ 476.0%	-3.40▼ 80.9%	-3.05▲ 10.3%	0.94▲ 130.8%	-1.04▼ 210.6%	3.32▲ 419.2%
EPS Growth %	-127.41%	1516.31%	-62.12%	-476%	-80.85%	10.29%	130.82%	-210.64%	419.23%
EPS (Basic)	-0.09	1.33	0.51	-1.88	-3.40	-3.05	0.95	-1.04	3.50
Diluted Shares Outstanding	11.55M	11.77M	12.04M	11.96M	12.6M	16.26M	18.19M	19.32M	21.23M
Basic Shares Outstanding	11.55M	11.68M	11.84M	11.96M	12.6M	16.26M	18M	19.32M	20.05M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

ANIP Balance Sheet

ANI Pharmaceuticals, Inc. (ANIP) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	131.6M	152.88M	187.69M	170.32M	321.77M	344.26M	519.82M	527.68M	753.12M
Cash & Short-Term Investments	31.14M	43.01M	62.33M	7.86M	100.3M	48.23M	221.12M	151.17M	285.58M
Cash Only	31.14M	43.01M	62.33M	7.86M	100.3M	48.23M	221.12M	144.86M	285.58M
Short-Term Investments	0	0	0	0	0	0	0	6.31M	0
Accounts Receivable	58.79M	64.84M	72.13M	95.79M	128.53M	165.44M	162.08M	221.73M	281.08M
Days Sales Outstanding	121.34	117.41	127.46	167.72	217.05	190.86	121.52	131.73	116.14
Inventory	37.73M	40.5M	48.16M	60.8M	81.69M	105.36M	111.2M	136.78M	143.07M
Days Inventory Outstanding	174.24	202.45	278.36	254.63	296.37	277.08	223.6	199.53	-
Other Current Assets	2.78M	4.52M	4M	0	3.67M	21.41M	25.42M	18.01M	43.38M
Total Non-Current Assets	280.53M	277.73M	269.09M	290.87M	449.82M	415.83M	384.61M	756.01M	687.26M
Property, Plant & Equipment	20.4M	38.09M	40.55M	41.27M	52.67M	43.25M	44.59M	56.86M	62.48M
Fixed Asset Turnover	8.67x	5.29x	5.09x	5.05x	4.10x	7.32x	10.92x	10.80x	14.14x
Goodwill	1.84M	3.58M	3.58M	3.58M	27.89M	28.22M	28.22M	59.99M	62.48M
Intangible Assets	229.79M	201.6M	180.39M	188.51M	294.12M	251.63M	209.01M	541.83M	479.53M
Long-Term Investments	800K	5.02M	0	5M	5M	0	6.2M	0	0
Other Non-Current Assets	5.04M	1.47M	6.25M	802K	2.21M	11.36M	5.87M	12.22M	13.71M
Total Assets	412.14M▲ 0%	430.6M▲ 4.5%	456.79M▲ 6.1%	461.19M▲ 1.0%	771.6M▲ 67.3%	760.09M▼ 1.5%	904.42M▲ 19.0%	1.28B▲ 41.9%	1.44B▲ 12.2%
Asset Turnover	0.43x	0.47x	0.45x	0.45x	0.28x	0.42x	0.54x	0.48x	0.61x
Asset Growth %	27.65%	4.48%	6.08%	0.96%	67.31%	-1.49%	18.99%	41.94%	12.21%
Total Current Liabilities	39.23M	165.55M	61.68M	78.56M	87.54M	99.44M	145.48M	193.68M	278.11M
Accounts Payable	3.63M	8.88M	14.61M	11.26M	22.97M	29.3M	36.68M	45.66M	62.58M
Days Payables Outstanding	16.76	44.41	84.42	47.16	83.32	77.07	73.76	66.6	-
Short-Term Debt	3.35M	115.72M	9.94M	13.24M	850K	850K	850K	9.17M	17.27M
Deferred Revenue (Current)	23.97M	711K	451K	80K	87K	0	0	0	0
Other Current Liabilities	29.94M	31.69M	20.33M	33.39M	44.27M	43.71M	65.73M	77.03M	260.84M
Current Ratio	3.35x	0.92x	3.04x	2.17x	3.68x	3.46x	3.57x	2.72x	2.71x
Quick Ratio	2.39x	0.68x	2.26x	1.39x	2.74x	2.40x	2.81x	2.02x	2.19x
Cash Conversion Cycle	278.81	275.45	321.41	375.19	430.1	390.87	271.36	264.66	-
Total Non-Current Liabilities	198.15M	67.79M	182.32M	186.93M	325.32M	322.11M	301.35M	661.49M	621.54M
Long-Term Debt	198.15M	67.3M	175.81M	172.44M	286.52M	285.67M	284.82M	614.92M	307.93M
Capital Lease Obligations	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	7.59M	9.49M	0	0	0	0
Other Non-Current Liabilities	0	496K	6.51M	14.48M	38.8M	36.44M	16.53M	46.57M	313.61M
Total Liabilities	237.38M	233.34M	244M	265.49M	412.86M	421.55M	446.82M	855.17M	899.65M
Total Debt	201.51M	183.01M	185.75M	185.69M	287.37M	286.52M	285.67M	624.09M	325.19M
Net Debt	170.36M	140.01M	123.42M	177.82M	187.07M	238.29M	64.55M	479.23M	39.61M
Debt / Equity	1.15x	0.93x	0.87x	0.95x	0.80x	0.85x	0.62x	1.46x	0.60x
Debt / EBITDA	3.58x	2.65x	3.05x	6.49x	38.53x	11.76x	2.68x	9.14x	1.61x
Net Debt / EBITDA	3.03x	2.03x	2.02x	6.21x	25.08x	9.78x	0.60x	7.02x	0.20x
Interest Coverage	2.35x	2.40x	1.26x	-1.69x	-3.34x	-1.26x	1.74x	0.03x	-
Total Equity	174.76M▲ 0%	197.26M▲ 12.9%	212.79M▲ 7.9%	195.7M▼ 8.0%	358.74M▲ 83.3%	338.54M▼ 5.6%	457.6M▲ 35.2%	428.53M▼ 6.4%	540.72M▲ 26.2%
Equity Growth %	3.01%	12.88%	7.87%	-8.03%	83.31%	-5.63%	35.17%	-6.35%	26.18%
Book Value per Share	15.13	16.76	17.67	16.36	28.48	20.82	25.15	22.18	25.47
Total Shareholders' Equity	174.76M	197.26M	212.79M	195.7M	358.74M	338.54M	457.6M	428.53M	540.72M
Common Stock	1K	1K	1K	1K	1K	1K	2K	2K	3K
Retained Earnings	-4.01M	11.49M	17.58M	-4.97M	-47.77M	-97.29M	-80.13M	-100.28M	-23.1M
Treasury Stock	-259K	-659K	-723K	-2.25M	-3.13M	-5.09M	-10.08M	-21.04M	0
Accumulated OCI	-6.59M	-379K	-4.87M	-11.44M	-3.06M	12.17M	8.86M	5.34M	1.03M
Minority Interest	0	0	0	0	0	0	0	0	0

ANIP Cash Flow Statement

ANI Pharmaceuticals, Inc. (ANIP) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	39.42M	67.07M	45.63M	15.27M	3.32M	-31.2M	118.96M	64.02M	185.22M
Operating CF Margin %	22.29%	33.27%	22.09%	7.32%	1.54%	-9.86%	24.44%	10.42%	20.97%
Operating CF Growth %	43.49%	70.16%	-31.97%	-66.54%	-78.24%	-1039.28%	481.24%	-46.19%	189.34%
Net Income	-1.08M	15.49M	6.09M	-22.55M	-42.6M	-47.9M	18.78M	-18.52M	78.34M
Depreciation & Amortization	27.93M	33.74M	44.61M	44.64M	47.25M	59.65M	59.79M	67.73M	91.42M
Stock-Based Compensation	6.09M	6.78M	9.22M	12.94M	10.49M	14.6M	20.65M	29.34M	37.93M
Deferred Taxes	3.56M	-5.18M	-9.13M	-13.21M	-16.75M	-15.25M	-11.74M	-21.91M	14.24M
Other Non-Cash Items	8.57M	10.27M	9.42M	6.07M	5.02M	8.99M	6.62M	18.56M	-36.7M
Working Capital Changes	-5.65M	5.97M	-14.58M	-12.63M	-84K	-51.3M	24.86M	-11.19M	0
Change in Receivables	-12.89M	-4.74M	-7.29M	-23.66M	-5.55M	-36.91M	3.36M	-21.09M	-58.53M
Change in Inventory	5.36M	-379K	-7.66M	-2.76M	3.22M	-23.63M	-5.84M	-21.29M	-5.96M
Change in Payables	3K	3.47M	5.04M	-2.29M	10.17M	5.04M	7.55M	479K	15.16M
Cash from Investing	-107.99M	-27.38M	-27.55M	-68.32M	-105.48M	-15.74M	-18.51M	-404.72M	-34.32M
Capital Expenditures	-107.99M	-10.91M	-27.55M	-6.13M	-2.56M	-8.88M	-8.87M	-16.24M	0
CapEx % of Revenue	61.07%	5.41%	13.34%	2.94%	1.18%	2.81%	1.82%	2.64%	-
Acquisitions	0	-16.47M	0	0	-84.49M	-33K	0	-401.28M	0
Investments	-	-	-	-	-	-	-	-	-
Other Investing	-97.62M	-5.17M	0	-62.19M	-18.43M	-6.83M	-9.64M	12.8M	-34.32M
Cash from Financing	72.36M	-27.82M	1.25M	-1.44M	194.59M	-5.13M	67.44M	264.94M	-9.94M
Debt Issued (Net)	75M	-2.81M	115.29M	-534K	99.02M	-3M	-3M	345.22M	0
Equity Issued (Net)	-259K	-659K	1000K	-1000K	1000K	-1000K	1000K	-1000K	0
Dividends Paid	0	0	0	0	-190K	-1.63M	-1.63M	-1.63M	-1.16M
Share Repurchases	-259K	-659K	-1.03M	-1.52M	-890K	-1.96M	-4.99M	-10.96M	-12.21M
Other Financing	-2.38M	-24.34M	-118.75M	618K	2.07M	1.46M	-3.5M	-67.69M	-8.79M
Net Change in Cash	3.78M▲ 0%	11.88M▲ 214.0%	19.33M▲ 62.7%	-54.49M▼ 381.9%	92.43M▲ 269.6%	-52.07M▼ 156.3%	167.89M▲ 422.4%	-76.23M▼ 145.4%	140.73M▲ 284.6%
Free Cash Flow	-68.57M▲ 0%	56.16M▲ 181.9%	18.08M▼ 67.8%	-53.05M▼ 393.4%	-20.32M▲ 61.7%	-47.66M▼ 134.6%	100.45M▲ 310.8%	47.06M▼ 53.1%	185.22M▲ 293.6%
FCF Margin %	-38.78%	27.86%	8.75%	-25.45%	-9.4%	-15.06%	20.63%	7.66%	20.97%
FCF Growth %	43.6%	181.9%	-67.8%	-393.41%	61.71%	-134.58%	310.77%	-53.15%	293.56%
FCF per Share	-5.94	4.77	1.50	-4.43	-1.61	-2.93	5.52	2.44	8.73
FCF Conversion (FCF/Net Income)	-36.63x	4.33x	7.49x	-0.68x	-0.08x	0.65x	6.33x	-3.46x	2.36x
Interest Paid	3.76M	6.29M	6.09M	6.93M	9.71M	21.48M	31.43M	24.38M	0
Taxes Paid	17.79M	6.4M	10.03M	4.98M	10.37M	288K	1.23M	19.06M	0

ANIP Key Ratios

ANI Pharmaceuticals, Inc. (ANIP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	2.39%	-0.62%	8.33%	2.97%	-11.04%	-15.37%	-13.74%	4.72%	-4.18%	16.16%
Return on Invested Capital (ROIC)	7.89%	6.99%	7.77%	3.64%	-3.38%	-6.49%	-4.71%	6.41%	0.06%	11.2%
Gross Margin	62.07%	55.31%	63.77%	69.42%	58.19%	53.45%	56.13%	62.71%	59.27%	-
Net Margin	3.06%	-0.61%	7.69%	2.95%	-10.82%	-19.71%	-15.14%	3.86%	-3.01%	8.87%
Debt / Equity	0.71x	1.15x	0.93x	0.87x	0.95x	0.80x	0.85x	0.62x	1.46x	0.60x
Interest Coverage	1.77x	2.35x	2.40x	1.26x	-1.69x	-3.34x	-1.26x	1.74x	0.03x	-
FCF Conversion	6.98x	-36.63x	4.33x	7.49x	-0.68x	-0.08x	0.65x	6.33x	-3.46x	2.36x
Revenue Growth	68.53%	37.49%	13.99%	2.47%	0.93%	3.67%	46.38%	53.87%	26.2%	43.78%

ANIP SEC Filings & Documents

ANI Pharmaceuticals, Inc. (ANIP) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 7, 2026·SEC

Material company update

Mar 3, 2026·SEC

Material company update

Feb 27, 2026·SEC

10-K Annual Reports

FY 2026

Feb 27, 2026·SEC

FY 2025

Feb 28, 2025·SEC

10-Q Quarterly Reports

FY 2025

Nov 7, 2025·SEC

FY 2025

Aug 8, 2025·SEC

FY 2025

May 9, 2025·SEC

ANIP Frequently Asked Questions

ANI Pharmaceuticals, Inc. (ANIP) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

ANI Pharmaceuticals, Inc. (ANIP) reported $883.4M in revenue for fiscal year 2025. This represents a 717728% increase from $0.1M in 1998.

ANI Pharmaceuticals, Inc. (ANIP) grew revenue by 43.8% over the past year. This is strong growth.

Yes, ANI Pharmaceuticals, Inc. (ANIP) is profitable, generating $78.3M in net income for fiscal year 2025 (8.9% net margin).

Dividend & Returns

ANI Pharmaceuticals, Inc. (ANIP) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.

ANI Pharmaceuticals, Inc. (ANIP) has a return on equity (ROE) of 16.2%. This is reasonable for most industries.

ANI Pharmaceuticals, Inc. (ANIP) generated $128.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More ANIP

ANI Pharmaceuticals, Inc. (ANIP) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

ANI Pharmaceuticals, Inc.(ANIP)Earnings, Financials & Key Ratios

ANIP Key Insights

✓Strengths

✗Weaknesses

ANIP Price & Volume

ANIP Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

ANIP Recent Earnings

ANIP Peer Comparison

Compare ANIP vs Peers

vs AMRX

vs MCK

Compare Top 5

ANIP Income Statement

ANIP Balance Sheet

ANIP Cash Flow Statement

ANIP Key Ratios

ANIP SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

ANIP Frequently Asked Questions

Explore More ANIP

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation